Urogen Pharma (URGN) stock surged 9.7% due to positive phase III study results

From Nasdaq: 2024-06-17 05:00:00

Urogen Pharma (URGN) shares surged by 9.7% in the last trading session to $19.20 due to solid volume. Data from the phase III ENVISION study on UGN-102 showed an 82.3% 12-month duration of response for patients with low-grade bladder cancer. The company is expected to post a quarterly loss of $0.88 per share with revenues of $23.69 million.

Regenxbio (RGNX) closed 5.1% lower at $12.41. The consensus EPS estimate for RGNX’s upcoming report has changed +0.9% in the past month to -$1.27. In past presidential election years, Bitcoin had returns: 2012 +272.4%, 2016 +161.1%, 2020 +302.8%. Zacks predicts another surge in the coming months.



Read more at Nasdaq: Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?